News - Bristol-Myers Squibb

Filter

Current filters:

Bristol-Myers Squibb

Popular Filters

80 to 104 of 222 results

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head

08-04-2013

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis

05-04-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility

05-04-2013

The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Xarelto and Eliquis set to displace current therapies in DVT/PE

28-03-2013

Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga

25-03-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Merck KGaA links with Bristol-Myers for Glucophage promotion in China

19-03-2013

German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

NICE green light for earlier use of Bristol-Myers' Orencia

08-03-2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) now recommends…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalRegulation

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri

04-03-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

AstraZenecaBiotechnologyBristol-Myers SquibbCell TherapeuticsDiabetesEuropeKomboglyzemetforminOncologyPharmaceuticalPixuvriPricingRegulationsaxagliptin

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds

26-02-2013

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those…

Bristol-Myers SquibbByettaDiabetesJanuviaMerck & CoPharmaceuticalResearch

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

Bristol-Myers beats expectations, as new products kick in

25-01-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) pleased investors, seeing its shares close up 2.6% at…

Bristol-Myers SquibbFinancialPharmaceutical

News briefs: Novartis drops Ruvise MAA; B-MS settlement; Germany donates to Global Fund

25-01-2013

The European Medicines Agency says it has been formally notified by Swiss drug major Novartis (NOVN:…

Anti-viralsBMS-986094Bristol-Myers SquibbFinancialLegalNovartisPharmaceuticalRare diseasesRegulationRuviseTropical diseases

Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis

23-01-2013

In final guidance published (January 23, 2013), UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbCardio-vascularEliquisEuropeJavlorOncologyPfizerPharmaceuticalPierre FabrePricingRegulation

UK's NICE issues draft guideline for diagnosis and management of hepatitis B

17-01-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) is currently developing…

Anti-viralsBaracludeBiotechnologyBristol-Myers SquibbEuropeGilead SciencesNovartisPharmaceuticalPreveonPricingRegulationSebivoViread

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

Scottish Medicines Consortium backs AstraZeneca/B-MS' Forxiga for type 2 diabetes

14-01-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

US FDA finally approves Bristol-Myers/Pfizer's Eliquis for stroke prevention in AF patients

31-12-2012

The US Food and Drug Administration on December 28 finally approved the anti-clotting drug Eliquis (apixaban),…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

80 to 104 of 222 results

Back to top